|
Towa Pharmaceutical Co., Ltd. (4553.T) DCF Valuation |
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Towa Pharmaceutical Co., Ltd. (4553.T) Bundle
Whether you're an investor or an analyst, this Towa Pharmaceutical Co., Ltd. (4553T) DCF Calculator is your go-to tool for accurate valuation. Loaded with real data from Towa Pharmaceutical, you can adjust forecasts and immediately observe the results.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 110,384.0 | 154,900.0 | 165,615.0 | 208,859.0 | 227,934.0 | 274,939.6 | 331,638.8 | 400,030.9 | 482,527.0 | 582,035.9 |
| Revenue Growth, % | 0 | 40.33 | 6.92 | 26.11 | 9.13 | 20.62 | 20.62 | 20.62 | 20.62 | 20.62 |
| EBITDA | 24,456.0 | 30,354.0 | 29,492.0 | 24,924.0 | 35,536.0 | 47,885.0 | 57,760.0 | 69,671.5 | 84,039.5 | 101,370.5 |
| EBITDA, % | 22.16 | 19.6 | 17.81 | 11.93 | 15.59 | 17.42 | 17.42 | 17.42 | 17.42 | 17.42 |
| Depreciation | 8,285.0 | 10,425.0 | 10,954.0 | 19,409.0 | 17,888.0 | 20,890.3 | 25,198.4 | 30,394.9 | 36,663.0 | 44,223.9 |
| Depreciation, % | 7.51 | 6.73 | 6.61 | 9.29 | 7.85 | 7.6 | 7.6 | 7.6 | 7.6 | 7.6 |
| EBIT | 16,171.0 | 19,929.0 | 18,538.0 | 5,515.0 | 17,648.0 | 26,994.7 | 32,561.7 | 39,276.7 | 47,376.5 | 57,146.7 |
| EBIT, % | 14.65 | 12.87 | 11.19 | 2.64 | 7.74 | 9.82 | 9.82 | 9.82 | 9.82 | 9.82 |
| Total Cash | 18,713.0 | 22,915.0 | 32,830.0 | 24,257.0 | 29,650.0 | 41,896.0 | 50,536.0 | 60,957.8 | 73,528.8 | 88,692.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 41,572.0 | 45,784.0 | 50,748.0 | 54,392.0 | 71,657.0 | 85,418.6 | 103,034.0 | 124,282.1 | 149,912.1 | 180,827.6 |
| Account Receivables, % | 37.66 | 29.56 | 30.64 | 26.04 | 31.44 | 31.07 | 31.07 | 31.07 | 31.07 | 31.07 |
| Inventories | 50,415.0 | 60,951.0 | 72,701.0 | 92,927.0 | 101,072.0 | 119,738.4 | 144,431.3 | 174,216.6 | 210,144.3 | 253,481.2 |
| Inventories, % | 45.67 | 39.35 | 43.9 | 44.49 | 44.34 | 43.55 | 43.55 | 43.55 | 43.55 | 43.55 |
| Accounts Payable | 10,691.0 | 11,869.0 | 17,041.0 | 31,284.0 | 26,372.0 | 29,795.6 | 35,940.2 | 43,351.9 | 52,292.1 | 63,076.1 |
| Accounts Payable, % | 9.69 | 7.66 | 10.29 | 14.98 | 11.57 | 10.84 | 10.84 | 10.84 | 10.84 | 10.84 |
| Capital Expenditure | -4,670.0 | -9,879.0 | -13,576.0 | -30,469.0 | -39,325.0 | -27,849.6 | -33,592.9 | -40,520.6 | -48,876.9 | -58,956.5 |
| Capital Expenditure, % | -4.23 | -6.38 | -8.2 | -14.59 | -17.25 | -10.13 | -10.13 | -10.13 | -10.13 | -10.13 |
| Tax Rate, % | 33.88 | 33.88 | 33.88 | 33.88 | 33.88 | 33.88 | 33.88 | 33.88 | 33.88 | 33.88 |
| EBITAT | 11,324.9 | 14,853.1 | 13,261.4 | 2,635.9 | 11,669.4 | 17,817.5 | 21,491.8 | 25,924.0 | 31,270.2 | 37,718.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -66,356.1 | 1,829.1 | -902.6 | -18,051.1 | -40,089.6 | -18,146.2 | -23,066.5 | -27,823.3 | -33,561.2 | -40,482.3 |
| WACC, % | 3.74 | 3.85 | 3.77 | 3.19 | 3.64 | 3.64 | 3.64 | 3.64 | 3.64 | 3.64 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -126,931.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -41,292 | |||||||||
| Terminal Value | -2,521,424 | |||||||||
| Present Terminal Value | -2,108,911 | |||||||||
| Enterprise Value | -2,235,842 | |||||||||
| Net Debt | 172,706 | |||||||||
| Equity Value | -2,408,548 | |||||||||
| Diluted Shares Outstanding, MM | 49 | |||||||||
| Equity Value Per Share | -48,933.84 |
Benefits You Will Receive
- Pre-Loaded Financial Model: Leverage Towa Pharmaceutical’s actual data for accurate DCF valuation.
- Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Automatic updates provide immediate feedback as you adjust inputs.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation analysis.
- Flexible and Reusable: Designed for adaptability, allowing repeated use for in-depth forecasts.
Highlighted Features
- Accurate Towa Financials: Gain access to reliable historical data and future forecasts specific to Towa Pharmaceutical Co., Ltd. (4553T).
- Adjustable Forecast Parameters: Modify yellow-highlighted cells, including WACC, growth rates, and profit margins.
- Real-Time Calculations: Enjoy automatic updates for DCF, Net Present Value (NPV), and cash flow analyses.
- User-Friendly Dashboard: Intuitive charts and summaries designed to effectively display your valuation findings.
- Designed for All Skill Levels: An accessible layout tailored for investors, CFOs, and consultants alike.
How It Functions
- Download the Template: Gain immediate access to the Excel-based Towa Pharmaceutical DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model promptly recalculates Towa Pharmaceutical's intrinsic value.
- Test Scenarios: Run various scenarios to assess how changes in assumptions affect valuation.
- Analyze and Decide: Leverage the results to inform your investment or financial analysis for Towa Pharmaceutical Co., Ltd. (4553T).
Why Opt for This Calculator?
- Reliable Data: Access accurate financial information for Towa Pharmaceutical Co., Ltd. to ensure trustworthy valuation outcomes.
- Fully Customizable: Tailor critical variables such as growth rates, WACC, and tax rates to align with your financial forecasts.
- Efficient: Pre-established calculations eliminate the hassle of starting from the ground up.
- Professional-Grade Resource: Crafted for investors, analysts, and consultants alike.
- User-Friendly Design: An intuitive interface and detailed guidance make it accessible for everyone.
Who Can Benefit from This Product?
- Professional Investors: Develop comprehensive and reliable valuation models for analyzing portfolios involving Towa Pharmaceutical Co., Ltd. (4553T).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Towa Pharmaceutical Co., Ltd. (4553T).
- Students and Educators: Utilize real-world data to enhance financial modeling skills and instruction.
- Healthcare Enthusiasts: Gain insights into the market valuation of pharmaceutical companies like Towa Pharmaceutical Co., Ltd. (4553T).
Contents of the Template
- Operating and Balance Sheet Data: Pre-filled historical data and forecasts for Towa Pharmaceutical Co., Ltd. (4553T), including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for calculating the Weighted Average Cost of Capital (WACC), featuring parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Customizable Discounted Cash Flow models illustrating intrinsic value along with comprehensive calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support in-depth analysis.
- Key Ratios: Includes ratios for profitability, leverage, and efficiency specifically for Towa Pharmaceutical Co., Ltd. (4553T).
- Dashboard and Charts: Visual representation of valuation results and underlying assumptions for straightforward analysis.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.